<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51882">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01808430</url>
  </required_header>
  <id_info>
    <org_study_id>CME-12-001</org_study_id>
    <nct_id>NCT01808430</nct_id>
  </id_info>
  <brief_title>Powered Echelon Device in VATS Surgery</brief_title>
  <official_title>Real World Outcomes of Video-Assisted Thoracoscopic Surgery for Lung Cancer Using ECHELON FLEX™ Powered ENDOPATH® Stapler: a Prospective European Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ethicon Endo-Surgery (Europe) GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ethicon Endo-Surgery (Europe) GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to collect real world outcomes of Video-Assisted Thoracoscopic Surgery
      (VATS) for lung cancer (lobectomy, wedge resection) using ECHELON FLEX™ Powered ENDOPATH®
      Staplers 45 mm and/or 60 mm (study devices).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The European prospective observational multi-center cohort study aims to collect real-world
      outcomes of consecutive patients scheduled for VATS lobectomy for histologically confirmed
      Non-Small Cell Lung Cancer (NSCLC) or scheduled for VATS wedge resection for undiagnosed
      pulmonary nodule or metastasis from colorectal cancer (CRC) in accordance with their
      institution's Standard-of-care (SOC).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>6 Weeks</target_duration>
  <primary_outcome>
    <measure>occurrence and duration of post-operative air leak</measure>
    <time_frame>prolonged air leak defined as longer than 5 days post-op</time_frame>
    <safety_issue>No</safety_issue>
    <description>occurrence and duration of prolonged air leak defined as longer than 5 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>volume of estimated intra-operative blood loss</measure>
    <time_frame>blood loss intra-op and up to 5 days post-op</time_frame>
    <safety_issue>No</safety_issue>
    <description>volume of estimated intra-operative blood loss</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Non-small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>VATS for NSCLC patients</arm_group_label>
    <description>VATS for confirmed non-small cell lung cancer (NSCLC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>VATS for confirmed non-small cell lung cancer (NSCLC)</intervention_name>
    <description>Video-Assisted Thoracoscopic Surgery for NSCLC patients</description>
    <arm_group_label>VATS for NSCLC patients</arm_group_label>
    <other_name>Video-Assisted Thoracoscopic Surgery</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for VATS lobectomy for histologically confirmed Non-Small Cell Lung
        Cancer (NSCLC) or scheduled for VATS wedge resection for undiagnosed pulmonary nodule or
        metastasis from colorectal cancer (CRC) in accordance with their institution's
        Standard-of-care (SOC).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed NSCLC (up to and including Stage II) for patients undergoing
             VATS lobectomy. For patients undergoing wedge resection for undiagnosed pulmonary
             nodule or metastasis from CRC, a malignant diagnosis may be confirmed
             post-operatively.

          -  Scheduled for lung resection surgery (lobectomy or wedge resection) involving only
             one lobe of the lung

          -  Willing to give consent and comply with evaluation and treatment schedule

          -  At least 18 years of age

        Exclusion Criteria:

          -  Active bacterial infection or fungal infection

          -  Systemic administration (intravenous or oral) of steroids (within 30 days prior to
             study procedure)

          -  Chemotherapy or radiation therapy for lung cancer may not be performed for 30 days
             prior to the procedure

          -  Scheduled concurrent surgical procedure other than wedge resection or lobectomy
             (central venous access - e.g. port placement, mediastinoscopy with lymph node
             sampling, and VATS lymphadenectomy are allowed);

          -  Prior history of VATS or open lung surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goran Ribaric, MD, MSc, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ethicon Endo-Surgery (Europe) GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Goran Ribaric, MD, MSc, PhD</last_name>
    <phone>+49-40-5297</phone>
    <phone_ext>3125</phone_ext>
    <email>gribaric@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Professor Peter Licht</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Licht, MD, PhD</last_name>
      <phone>+45 (6541) 3385</phone>
      <email>peter.licht@regionsyddanmark.dk</email>
    </contact>
    <investigator>
      <last_name>Peter Licht, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>March 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
